Santhera Financial Statements From 2010 to 2025
| SPHDF Stock | USD 9.42 0.00 0.00% |
Check Santhera Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Santhera Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Santhera financial statements analysis is a perfect complement when working with Santhera Pharmaceuticals Valuation or Volatility modules.
Santhera |
Santhera Pharmaceuticals Holding Company Return On Equity Analysis
Santhera Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Santhera Pharmaceuticals Return On Equity | -13.16 |
Most of Santhera Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Santhera Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Santhera Pharmaceuticals Holding has a Return On Equity of -13.1615. This is 45.09% lower than that of the Healthcare sector and 63.9% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Santhera Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Santhera Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Santhera Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Santhera Pharmaceuticals competition to find correlations between indicators driving Santhera Pharmaceuticals's intrinsic value. More Info.Santhera Pharmaceuticals Holding is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Santhera Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Santhera Pharmaceuticals Financial Statements
Santhera Pharmaceuticals stakeholders use historical fundamental indicators, such as Santhera Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Santhera Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Santhera Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Santhera Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Santhera Pharmaceuticals Holding. Please read more on our technical analysis and fundamental analysis pages.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland. SANTHERA PHARMACEUTICALS operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs people.
Currently Active Assets on Macroaxis
Other Information on Investing in Santhera Pink Sheet
Santhera Pharmaceuticals financial ratios help investors to determine whether Santhera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santhera with respect to the benefits of owning Santhera Pharmaceuticals security.